JP2008525460A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008525460A5 JP2008525460A5 JP2007548380A JP2007548380A JP2008525460A5 JP 2008525460 A5 JP2008525460 A5 JP 2008525460A5 JP 2007548380 A JP2007548380 A JP 2007548380A JP 2007548380 A JP2007548380 A JP 2007548380A JP 2008525460 A5 JP2008525460 A5 JP 2008525460A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- composition
- nucleotides
- interfering rna
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002773 nucleotide Substances 0.000 claims 48
- 125000003729 nucleotide group Chemical group 0.000 claims 48
- 230000000692 anti-sense effect Effects 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 32
- 108020004999 messenger RNA Proteins 0.000 claims 26
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 22
- 230000002452 interceptive effect Effects 0.000 claims 22
- 230000000295 complement effect Effects 0.000 claims 12
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 claims 10
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 claims 10
- 230000004962 physiological condition Effects 0.000 claims 6
- 239000003937 drug carrier Substances 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 4
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 230000002238 attenuated effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 claims 1
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63870504P | 2004-12-23 | 2004-12-23 | |
| US60/638,705 | 2004-12-23 | ||
| PCT/US2005/046064 WO2006069037A1 (en) | 2004-12-23 | 2005-12-19 | Rnai inhibition of ctgf for treatment of ocular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012029499A Division JP2012097119A (ja) | 2004-12-23 | 2012-02-14 | 眼の障害を処置するためのＣＴＧＦのＲＮＡｉ阻害 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008525460A JP2008525460A (ja) | 2008-07-17 |
| JP2008525460A5 true JP2008525460A5 (cg-RX-API-DMAC7.html) | 2009-02-12 |
| JP5095414B2 JP5095414B2 (ja) | 2012-12-12 |
Family
ID=36218404
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007548380A Expired - Fee Related JP5095414B2 (ja) | 2004-12-23 | 2005-12-19 | 眼の障害を処置するためのＣＴＧＦのＲＮＡｉ阻害 |
| JP2012029499A Withdrawn JP2012097119A (ja) | 2004-12-23 | 2012-02-14 | 眼の障害を処置するためのＣＴＧＦのＲＮＡｉ阻害 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012029499A Withdrawn JP2012097119A (ja) | 2004-12-23 | 2012-02-14 | 眼の障害を処置するためのＣＴＧＦのＲＮＡｉ阻害 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US7622454B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP1827503A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP5095414B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20070091337A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101160138B (cg-RX-API-DMAC7.html) |
| AR (1) | AR052172A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2005319279B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0516377A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2591611A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2007007654A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI386225B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2006069037A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200704932B (cg-RX-API-DMAC7.html) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006223131A1 (en) | 2005-03-11 | 2006-09-21 | Alcon, Inc. | RNAi-mediated inhibition of frizzled related protein-1 for treatment of glaucoma |
| US20060275797A1 (en) * | 2005-03-21 | 2006-12-07 | Alcon Manufacturing, Ltd. | Use of agents which inhibit connective tissue growth factor (CTGF) binding and signaling via the TrkA/p75NTR receptor complex for the prevention and treatment of CTGF-mediated ocular disorders |
| WO2009046059A1 (en) * | 2007-10-01 | 2009-04-09 | Alcon Research, Ltd. | Self complementary aav-mediated delivery of interfering rna molecules to treat or prevent ocular disorders |
| US7973019B1 (en) | 2007-10-03 | 2011-07-05 | Alcon Research, Ltd. | Transferrin/transferrin receptor-mediated siRNA delivery |
| AR069328A1 (es) | 2007-11-15 | 2010-01-13 | Alcon Mfg Ltd | Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad |
| TW200932274A (en) | 2007-12-18 | 2009-08-01 | Alcon Res Ltd | Interfering RNA delivery system and uses thereof |
| US8446125B2 (en) | 2008-06-20 | 2013-05-21 | Superior Communications, Inc. | Vehicle power charger |
| US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| KR101877698B1 (ko) | 2008-08-25 | 2018-07-12 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| EP2334319B1 (en) * | 2008-08-25 | 2017-12-06 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to ctgf |
| US8664189B2 (en) | 2008-09-22 | 2014-03-04 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| EP2408916A2 (en) * | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| CN106074591B (zh) | 2010-03-24 | 2020-01-14 | 菲奥医药公司 | 眼部症候中的rna干扰 |
| US9340786B2 (en) * | 2010-03-24 | 2016-05-17 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
| KR101249041B1 (ko) * | 2010-04-28 | 2013-03-29 | 포항공과대학교 산학협력단 | 결합조직 성장인자를 이용한 약학적 조성물 |
| US9241944B2 (en) * | 2010-06-16 | 2016-01-26 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Methods and compositions for stimulating reepithelialisation during wound healing |
| ES2732929T3 (es) | 2010-10-22 | 2019-11-26 | Olix Pharmaceuticals Inc | Moléculas de ácido nucleico que inducen interferencia de ARN y usos de las mismas |
| JP2014505666A (ja) | 2010-11-18 | 2014-03-06 | ザ ジェネラル ホスピタル コーポレイション | 癌治療のための降圧剤の組成物および使用 |
| PT2670411T (pt) * | 2011-02-02 | 2019-06-18 | Excaliard Pharmaceuticals Inc | Compostos anti sentido visando um fator de crescimento do tecido conetivo (ctfg) para utilização num método de tratamento de queloides ou cicatrizes hipertróficas |
| CN102727513B (zh) * | 2011-04-15 | 2014-07-09 | 百奥迈科生物技术有限公司 | 靶向于组织因子基因的小核酸及其用途 |
| WO2012161677A1 (en) | 2011-05-20 | 2012-11-29 | Alcon Research, Ltd. | TRANSFERRIN/TRANSFERRIN RECEPTOR-MEDIATED siRNA DELIVERY |
| US8802839B2 (en) * | 2011-07-15 | 2014-08-12 | Fibrogen, Inc. | Connective tissue growth factor antisense oligonucleotides |
| US20130178421A1 (en) | 2012-01-06 | 2013-07-11 | Alcon Research, Ltd. | Interfering rna delivery system and uses thereof |
| EP2805713B1 (en) | 2012-01-18 | 2018-10-10 | Bioneer Corporation | Magnetic nanoparticle-samirna complex and method for preparing same |
| EP3514236A1 (en) | 2012-05-22 | 2019-07-24 | Olix Pharmaceuticals, Inc. | Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
| KR101862349B1 (ko) | 2013-07-05 | 2018-05-31 | (주)바이오니아 | 개선된 고효율 나노입자형 올리고뉴클레오타이드 구조체 및 그의 제조방법 |
| JP2016525346A (ja) | 2013-07-05 | 2016-08-25 | バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ | 呼吸器疾患関連遺伝子特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含む呼吸器疾患予防または治療用組成物 |
| JP6368363B2 (ja) | 2013-07-05 | 2018-08-01 | バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ | デングウィルス特異的ｓｉＲＮＡ、そのようなｓｉＲＮＡを含む二重らせんオリゴＲＮＡ構造体およびこれを含むデングウィルス増殖抑制用組成物 |
| EP3077050B1 (en) * | 2013-12-04 | 2020-10-21 | Phio Pharmaceuticals Corp. | Methods for treatment of wound healing utilizing chemically modified oligonucleotides |
| US10208309B2 (en) | 2014-04-04 | 2019-02-19 | Bioneer Corporation | Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases |
| WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
| US10314690B1 (en) * | 2014-05-12 | 2019-06-11 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US10583221B2 (en) | 2014-05-12 | 2020-03-10 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US11045352B2 (en) | 2014-05-12 | 2021-06-29 | Gholam A. Peyman | Methods for treatment of dry eye and other acute or chronic inflammatory processes |
| US11338059B2 (en) | 2014-05-12 | 2022-05-24 | Gholam A. Peyman | Method of corneal and scleral inlay crosslinking and preservation |
| US11666777B2 (en) | 2014-05-12 | 2023-06-06 | Gholam A. Peyman | Photodynamic therapy technique for preventing damage to the fovea of the eye or another body portion of a patient |
| US11565023B2 (en) | 2014-05-12 | 2023-01-31 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US11648261B2 (en) | 2014-05-12 | 2023-05-16 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US10881503B2 (en) | 2014-05-12 | 2021-01-05 | Gholam A. Peyman | Method of corneal transplantation or corneal inlay implantation with cross-linking |
| US12396889B2 (en) | 2014-05-12 | 2025-08-26 | Gholam A. Peyman | Lamellar corneal autologous or homologous graft in refractive surgery |
| US10925889B2 (en) | 2014-05-12 | 2021-02-23 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| CN107852029B (zh) | 2015-05-04 | 2022-05-27 | 科罗拉多州立大学董事会公司实体 | 无线电力传输 |
| EP3377630A4 (en) | 2015-11-16 | 2020-01-01 | Olix Pharmaceuticals, Inc. | Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3 |
| US11433136B2 (en) | 2015-12-18 | 2022-09-06 | The General Hospital Corporation | Polyacetal polymers, conjugates, particles and uses thereof |
| JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ，インコーポレーテッド | ＩＬ４Ｒα、ＴＲＰＡ１、またはＦ２ＲＬ１を標的とするＲＮＡ複合体を用いたアトピー性皮膚炎および喘息の治療 |
| US10519449B2 (en) | 2016-02-02 | 2019-12-31 | Olix Pharmaceuticals, Inc. | Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB |
| KR102339886B1 (ko) | 2016-04-11 | 2021-12-17 | 올릭스 주식회사 | 연결 조직 성장 인자를 표적화하는 rna 복합체를 사용한 특발성 폐 섬유증의 치료 방법 |
| KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
| JP7424728B2 (ja) | 2017-02-10 | 2024-01-30 | オリック パルマセゥティカルズ インコーポレイテッド | Ｒｎａ干渉のための長鎖の二本鎖ｒｎａ |
| US10363833B2 (en) * | 2017-03-15 | 2019-07-30 | Ford Global Technologies, Llc | Inductive charging active suspension |
| WO2019066519A1 (ko) * | 2017-09-28 | 2019-04-04 | 올릭스 주식회사 | 결합 조직 성장 인자를 표적으로 하는 rna 복합체를 함유하는 노인성 황반변성의 예방 또는 치료용 약학 조성물 |
| KR20200014684A (ko) * | 2018-07-31 | 2020-02-11 | 주식회사 레모넥스 | Ctgf 발현 억제용 조성물 |
| US11707518B2 (en) | 2019-04-28 | 2023-07-25 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| US12226478B2 (en) | 2019-04-28 | 2025-02-18 | Gholam A. Peyman | Method of treating, reducing, or alleviating a medical condition in a patient |
| CN110144350A (zh) * | 2019-05-15 | 2019-08-20 | 基诺泰康生物科技(北京)有限公司 | 一种特异性抑制CTGF基因表达的siRNA及其在抑制癜痕形成中的应用 |
| KR102757180B1 (ko) | 2019-11-22 | 2025-01-21 | (주)바이오니아 | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
| CN115698287A (zh) * | 2020-05-26 | 2023-02-03 | 奥利克斯医药有限公司 | 靶向MyD88的RNAi制剂以及其用途 |
| CN114807127A (zh) * | 2021-01-19 | 2022-07-29 | 陈璞 | 用于结缔组织生长因子的小干扰rna及其应用 |
| EP4536197A1 (en) | 2022-06-07 | 2025-04-16 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| WO2025147949A1 (zh) * | 2024-01-11 | 2025-07-17 | 广州瑞风生物科技有限公司 | 基因编辑系统及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7384634B2 (en) | 1991-08-30 | 2008-06-10 | University Of South Florida | Connective tissue growth factor |
| US5408040A (en) | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
| US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| CZ333294A3 (en) * | 1992-07-02 | 1995-07-12 | Hybridon | Self-stabilized oligonucleotide and inhibition method of virus gene or pathogenic organism or cellular gene expression |
| US5734039A (en) * | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
| US7041548B1 (en) * | 1996-07-16 | 2006-05-09 | Micron Technology, Inc. | Methods of forming a gate stack that is void of silicon clusters within a metallic silicide film thereof |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6348329B1 (en) | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
| US7115390B1 (en) | 1998-12-14 | 2006-10-03 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| EP2314700A1 (en) | 1999-01-28 | 2011-04-27 | Medical College of Georgia Research Institute, Inc | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded RNA |
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
| IL151781A0 (en) | 2000-03-16 | 2003-04-10 | Genetica Inc | Methods and compositions for rna interference |
| DE60140676D1 (de) | 2000-03-30 | 2010-01-14 | Massachusetts Inst Technology | Mediatoren von rns-interferenz, die rns-sequenzspezifisch sind |
| CZ308053B6 (cs) | 2000-12-01 | 2019-11-27 | Max Planck Gesellschaft | Izolovaná molekula dvouřetězcové RNA, způsob její výroby a její použití |
| JP4779255B2 (ja) | 2001-07-16 | 2011-09-28 | パナソニック株式会社 | レーザ光源 |
| JP2005519881A (ja) * | 2001-12-11 | 2005-07-07 | ファイブローゲン、インコーポレーテッド | 眼プロセスの抑制方法 |
| EP2221054A1 (en) * | 2002-04-30 | 2010-08-25 | Alcon, Inc. | CDK inhibitors for lowering intraocular pressure |
| CA2524569C (en) | 2002-05-03 | 2013-10-22 | Duke University | A method of regulating gene expression |
| WO2004014933A1 (en) | 2002-08-07 | 2004-02-19 | University Of Massachusetts | Compositions for rna interference and methods of use thereof |
| EP1534832A2 (en) | 2002-09-04 | 2005-06-01 | Provost, Fellows and Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin | Compositions and methods for tissue specific or inducible inhibition of gene expression |
| AU2003249012A1 (en) * | 2002-09-30 | 2004-04-23 | Japan As Represented By The President Of The University Of Tokyo | Genes and polypeptides relating to human myeloid leukemia |
| US20040175732A1 (en) | 2002-11-15 | 2004-09-09 | Rana Tariq M. | Identification of micrornas and their targets |
| MXPA05007651A (es) | 2003-01-16 | 2005-10-26 | Univ Pennsylvania | Composiciones y metodos para la inhibicion por arnsi de la molecula de adhesion intercelular-1. |
| AU2003224132A1 (en) * | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| WO2004099372A2 (en) * | 2003-05-01 | 2004-11-18 | University Of Florida | Anti-scarring ribozymes and methods |
| JPWO2004096277A1 (ja) * | 2003-05-01 | 2006-07-13 | 国立大学法人京都大学 | 眼内血管新生疾患の予防又は治療剤 |
| CA2519835A1 (en) * | 2003-05-28 | 2004-12-09 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection |
| GB0403600D0 (en) | 2004-02-18 | 2004-03-24 | Trinity College Dublin | Methods and reagents for treating disease |
| GB0404209D0 (en) | 2004-02-25 | 2004-03-31 | Uws Ventures Ltd | Materials and methods for treatment of allergic disease |
-
2005
- 2005-11-24 TW TW094141307A patent/TWI386225B/zh not_active IP Right Cessation
- 2005-12-19 KR KR1020077016318A patent/KR20070091337A/ko not_active Ceased
- 2005-12-19 US US11/313,200 patent/US7622454B2/en not_active Expired - Fee Related
- 2005-12-19 JP JP2007548380A patent/JP5095414B2/ja not_active Expired - Fee Related
- 2005-12-19 CA CA002591611A patent/CA2591611A1/en not_active Abandoned
- 2005-12-19 CN CN2005800479231A patent/CN101160138B/zh not_active Expired - Fee Related
- 2005-12-19 BR BRPI0516377-3A patent/BRPI0516377A/pt not_active IP Right Cessation
- 2005-12-19 ZA ZA200704932A patent/ZA200704932B/xx unknown
- 2005-12-19 EP EP05857141A patent/EP1827503A1/en not_active Withdrawn
- 2005-12-19 EP EP10010890A patent/EP2319543A1/en not_active Withdrawn
- 2005-12-19 AU AU2005319279A patent/AU2005319279B2/en not_active Ceased
- 2005-12-19 MX MX2007007654A patent/MX2007007654A/es active IP Right Grant
- 2005-12-19 WO PCT/US2005/046064 patent/WO2006069037A1/en not_active Ceased
- 2005-12-20 AR ARP050105371A patent/AR052172A1/es unknown
-
2009
- 2009-10-12 US US12/577,267 patent/US7838507B2/en not_active Expired - Fee Related
-
2010
- 2010-10-08 US US12/901,019 patent/US20110028534A1/en not_active Abandoned
-
2012
- 2012-02-14 JP JP2012029499A patent/JP2012097119A/ja not_active Withdrawn
-
2013
- 2013-12-05 US US14/097,928 patent/US20140094502A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008525460A5 (cg-RX-API-DMAC7.html) | ||
| Drag et al. | Gene therapy for retinal degenerative diseases: progress, challenges, and future directions | |
| JP6924744B2 (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| TWI528963B (zh) | 治療或預防眼科疾病的方法 | |
| ES2563984T3 (es) | Métodos para el tratamiento de trastornos oculares | |
| JP2022031772A5 (cg-RX-API-DMAC7.html) | ||
| RU2011124528A (ru) | ОПОСРЕДОВАННОЕ PHKI ИНГИБИРОВАНИЕ Rho-КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГЛАЗНЫХ НАРУШЕНИЙ | |
| JP2020158533A (ja) | 眼科症状を処置するまたは予防するための方法 | |
| JP2010501188A5 (cg-RX-API-DMAC7.html) | ||
| RU2008130857A (ru) | Опосредованное phkи ингибирование hif1a для лечения глазного ангиогенеза | |
| JP2017516461A (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2009540011A5 (cg-RX-API-DMAC7.html) | ||
| BRPI0516377A (pt) | inibição de rnai de ctgf para tratamento de distúrbios oculares | |
| JP2017532038A5 (cg-RX-API-DMAC7.html) | ||
| RU2008150324A (ru) | Iphk-опосредованное ингибирование связанных с фактором некроза опухоли альфа состояний | |
| JP2012525399A5 (cg-RX-API-DMAC7.html) | ||
| CN108291225A (zh) | 单链反义寡核苷酸在预防或治疗涉及三核苷酸重复扩增的遗传疾病中的用途 | |
| JP2009533475A5 (cg-RX-API-DMAC7.html) | ||
| JP6771387B2 (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP2009544734A5 (cg-RX-API-DMAC7.html) | ||
| JPWO2020061177A5 (cg-RX-API-DMAC7.html) | ||
| JP2018521669A (ja) | 治療用オリゴヌクレオチド | |
| JP2025107451A (ja) | 緑内障を治療するためのＷｎｔ５ａの調節 | |
| US20190144865A1 (en) | Modified tgf-beta oligonucleotide for use in a method of preventing and/or treating an ophthalmic disease | |
| JP2009533466A5 (cg-RX-API-DMAC7.html) |